News
-
-
-
PRESS RELEASE
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24
enVVeno Medical Corporation reports $4.0 million cash burn in Q1 in line with projections. Cash position sufficient for operations post-FDA decision of VenoValve. FDA decision expected in H2 2025 -
-
-
-
-
-
-